The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Carcinoma; Endometrial cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms ADELE
- 07 Mar 2022 Planned initiation date changed from 13 Dec 2021 to 31 Mar 2022.
- 27 Oct 2021 Planned initiation date changed from 30 Apr 2021 to 13 Dec 2021.
- 18 Mar 2021 New trial record